John Dobak Biography and Net Worth

CEO of DermTech

John Dobak, M.D. has served on our Board since the completion of the Business Combination in August 2019 and served on DermTech Operations’ board of directors between June 2012 and August 2019. Dr. Dobak has served as our Chief Executive Officer since the completion of the Business Combination in August 2019 and served as Chief Executive Officer of DermTech Operations between June 2012 and August 2019. From 2006 until 2011, Dr. Dobak served as the founder and Chief Executive Officer of Lithera, Inc., a pharmaceutical company developing an injectable product for dermatology. Dr. Dobak is the founder and President of the JAKK Group, a life sciences technology accelerator, which has created several companies including Lithera, Inc., INNERCOOL Therapies, Inc., CryoGen, Inc., and CryoCor, Inc. Dr. Dobak’s companies have developed and marketed therapeutics devices for endovascular hypothermia, cryosurgical cardiac catheters, and endometrial ablation. Dr. Dobak received a Bachelor’s Degree from the University of California, Los Angeles and a Medical Doctorate from the University of California, San Diego. Dr. Dobak is qualified to serve on our Board because of his service as DermTech Operations’ Chief Executive Officer, his service as a member of DermTech Operations’ board of directors and his experience founding and operating multiple companies in the life sciences industry. Provided by Tagnifi.

What is John Dobak's net worth?: The estimated net worth of John Dobak is at least $0.00 as of March 13th, 2023. Dr. Dobak owns 698,693 shares of DermTech stock worth more than $0 as of March 31st. This net worth estimate does not reflect any other investments that Dr. Dobak may own. Learn More about John Dobak's net worth.
How do I contact John Dobak?: The corporate mailing address for Dr. Dobak and other DermTech executives is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. DermTech can also be reached via phone at (858) 450-4222 and via email at investorrelations@dermtech.com. Learn More on John Dobak's contact information.
Has John Dobak been buying or selling shares of DermTech?: John Dobak has not been actively trading shares of DermTech within the last three months. Most recently, John Dobak sold 1,559 shares of the business's stock in a transaction on Monday, March 13th. The shares were sold at an average price of $3.26, for a transaction totalling $5,082.34. Following the completion of the sale, the chief executive officer now directly owns 698,693 shares of the company's stock, valued at $2,277,739.18. Learn More on John Dobak's trading history.
Who are DermTech's active insiders?: DermTech's insider roster includes John Dobak (CEO), Claudia Ibarra (COO), Scott Pancoast (Director), Enrico Picozza (Director), Kevin Sun (CFO), and Todd Wood (Insider). Learn More on DermTech's active insiders.

John Dobak Insider Trading History at DermTech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2023	Sell	1,559	$3.26	$5,082.34	698,693
3/7/2023	Sell	23,955	$4.06	$97,257.30	643,845
3/11/2022	Sell	1,326	$14.55	$19,293.30
3/7/2022	Sell	2,561	$13.03	$33,369.83
12/13/2021	Sell	1,964	$16.71	$32,818.44
12/8/2021	Sell	1,119	$18.46	$20,656.74
9/13/2021	Sell	1,899	$36.19	$68,724.81	453,645
9/8/2021	Sell	1,162	$36.19	$42,052.78
7/1/2021	Sell	12,500	$41.08	$513,500.00	459,647
6/11/2021	Sell	7,651	$41.08	$314,303.08	468,847
6/8/2021	Sell	1,118	$43.43	$48,554.74	476,498
6/1/2021	Sell	2,970	$40.22	$119,453.40	487,146
5/3/2021	Sell	25,000	$40.96	$1,024,000.00	499,095
4/27/2021	Sell	25,000	$51.35	$1,283,750.00	515,116
4/12/2021	Sell	25,000	$46.34	$1,158,500.00	550,773
3/8/2021	Sell	780	$50.04	$39,031.20
12/8/2020	Sell	786	$11.86	$9,321.96	541,683
9/10/2020	Sell	2,470	$10.82	$26,725.40	543,379

John Dobak Buying and Selling Activity at DermTech

DermTech Company Overview

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

Today's Range

Now: N/A

50 Day Range

MA: $0.19

$0.05

$0.42

2 Week Range

Now: N/A

Volume

3,662,300 shs

Average Volume

1,065,175 shs

Market Capitalization

$3.29 million

P/E Ratio

N/A

Dividend Yield